Vistin Pharma Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Vistin Pharma.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth15.9%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Here's Why Vistin Pharma (OB:VISTN) Has Caught The Eye Of Investors

Sep 18
Here's Why Vistin Pharma (OB:VISTN) Has Caught The Eye Of Investors

Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?

Feb 23
Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?

A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)

Sep 09
A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)

Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)

Aug 25
Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)

Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First

Mar 15
Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First

We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate

Feb 20
We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate

Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?

Jan 29
Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?

The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It

Jan 08
The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It

Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?

Dec 16
Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?

Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?

Nov 26
Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vistin Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OB:VISTN - Analysts future estimates and past financials data (NOK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20244276156100N/A
6/30/2024441682162N/A
3/31/2024441563574N/A
12/31/2023438467391N/A
9/30/2023439453977N/A
6/30/2023410144180N/A
3/31/20233737-2917N/A
12/31/2022305-5-75-11N/A
9/30/2022272-15-90-51N/A
6/30/2022243-7-97-54N/A
3/31/20222411-51-5N/A
12/31/202127925-1814N/A
9/30/202126526-1942N/A
6/30/202125730-2447N/A
3/31/202126343-186-129N/A
12/31/2020254-97-199-146N/A
9/30/2020246-102-174-133N/A
6/30/2020259-46-147-126N/A
3/31/2020247-671934N/A
12/31/201922866119N/A
9/30/20192124-14-8N/A
6/30/2019196-59-32-24N/A
3/31/2019190-72-60-40N/A
12/31/2018201-68-58-39N/A
9/30/2018200-16-33-5N/A
6/30/2018194-8N/A-22N/A
3/31/20181868N/A13N/A
12/31/20171755N/A10N/A
9/30/201716810N/A6N/A
6/30/20171607N/A41N/A
3/31/201717014N/A25N/A
12/31/201617316N/A54N/A
9/30/201639340N/A100N/A
6/30/201644646N/A60N/A
12/31/201537633N/A53N/A
12/31/2014361-62N/A17N/A
12/31/20133478N/A21N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if VISTN's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if VISTN's earnings are forecast to grow faster than the Norwegian market

High Growth Earnings: Insufficient data to determine if VISTN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if VISTN's revenue is forecast to grow faster than the Norwegian market.

High Growth Revenue: Insufficient data to determine if VISTN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VISTN's Return on Equity is forecast to be high in 3 years time


Discover growth companies